Non-coding RNAs: Multiple Players in Human Diseases

A special issue of Non-Coding RNA (ISSN 2311-553X).

Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 9444

Special Issue Editor

Special Issue Information

Dear Colleagues,

Non-coding RNAs (ncRNAs) are a class of RNA molecules that are biologically functional but not translatable into a protein. Initially, ncRNAs referred to tRNAs and rRNAs. The ncRNA field has witnessed rapid growth, identifying several new classes of ncRNAs with the application of next-generation sequencing technologies. The new species of ncRNAs include small nuclear ribonucleic acid (snRNAs), small nucleolar RNAs (snoRNAs), microRNAs (miRNAs), small interference RNAs (siRNAs), piwi-interacting RNAs (piRNAs), extracellular RNAs (exRNAs), long non-coding RNA (lncRNAs), small Cajal body-specific RNAs (scaRNAs), and circular RNAs (circRNAs).

Although the approximate number of ncRNAs encoded within the mammalian genome has not been determined precisely, recent transcriptomic and bioinformatic studies predict the existence of a large quantity of ncRNAs in the human genome.

Functionally, many ncRNAs play essentially regulatory roles at transcriptional and post-transcriptional levels epigenetically via various molecular mechanisms, such as heterochromatin formation, DNA methylation, histone modifications, and physical interactions with chromatin-modifying proteins to recruit them to specific loci in the genome for chromatin remodeling and transcriptional regulation. Particularly, the large intergenic non-coding RNAs (lincRNAs) are associated with chromatin-modifying complexes that target specific genomic loci to promote specific epigenetic states.

Numerous reports have documented the regulation of ncRNAs, particularly miRNAs and lncRNAs, in a wide range of cellular processes. Consequently, they significantly contribute to the regulation of the reproduction, regeneration, growth, development, and aging of organisms, particularly in mammals, and to pathogenesis of many diseases, such as tumorigenesis neurological disorders and heart/kidney diseases. Indeed, the emerging evidence has linked the aberrant generation of lncRNAs to down-regulation of the tumor suppressor genes and activation of the oncogenes.

A previous Special Issue in Cells, entitled “Non-coding RNAs: Epigenetic Players Implicated in Human Diseases”, was very successful, and comprises eight papers and reviews concerning various aspects of neuropsychiatric diseases. However, ncRNA is a broad and hot research field. It is difficult to cover it in one Special Issue. Therefore, we aim to work towards creating an additional Special Issue on this topic.

This Special Issue will focus on ncRNAs, particularly cirRNAs and lncRNAs, while other small RNAs, such as miRNAs and piRNAs, are also included due to their extensive functional characterization and the emerging interest on their therapeutic potential for stubborn diseases, such as neurological disorders and cancers.

We invite investigators in the field of ncRNAs and ncRNAs-mediated diseases, such as neurodegenerative diseases, cardiac diseases, hematological diseases, and cancers, to contribute original research articles as well as review articles. Potential topics include but are not limited to the following:

  • Bioinformatic and transcriptomic tools for the identification and characterization of ncRNAs, particularly the unclassified ncRNAs;
  • The latest technologies for predicting the structure and function of novel cirRNAs and lncRNAs in model and non-model organisms;
  • Distribution and characterization of ncRNAs in transcriptomes among the model and non-model organisms;
  • Regulation, functions, and mechanism of lncRNAs and cirRNAs in a wide range of cell processes, such as the metabolic pathways;
  • Potential links between the aberrant expression levels of ncRNAs and pathogenesis of some stubborn diseases, including cancer, neurological disorders, heart /kidney diseases;
  • Recent developments in the diagnosis of cancers, neurological diseases, and other genetic diseases with the implications of ncRNAs;
  • Targeting or delivery ncRNAs for therapy of cancer, neurological diseases, etc.;
  • Epitranscriptome modifications of lncRNAs in reproduction, regeneration, growth, development, and aging.

Please note: Any manuscripts solely based on public datasets without biological validations are not considered for deep review.

You may choose our Joint Special Issue in Cells.

Dr. Yujing Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Non-Coding RNA is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-coding RNA
  • human disease
  • epigenetic marker
  • therapy
  • pathogenesis
  • transcriptome

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 866 KiB  
Review
Circular RNAs, Noncoding RNAs, and N6-methyladenosine Involved in the Development of MAFLD
by Moeka Nakashima, Naoko Suga, Yuka Ikeda, Sayuri Yoshikawa and Satoru Matsuda
Non-Coding RNA 2024, 10(1), 11; https://doi.org/10.3390/ncrna10010011 - 5 Feb 2024
Cited by 3 | Viewed by 3052
Abstract
Noncoding RNAs (ncRNAs), including circular RNAs (circRNAs) and N6-methyladenosine (m6A), have been shown to play a critical role in the development of various diseases including obesity and metabolic disorder-associated fatty liver disease (MAFLD). Obesity is a chronic disease caused by excessive fat accumulation [...] Read more.
Noncoding RNAs (ncRNAs), including circular RNAs (circRNAs) and N6-methyladenosine (m6A), have been shown to play a critical role in the development of various diseases including obesity and metabolic disorder-associated fatty liver disease (MAFLD). Obesity is a chronic disease caused by excessive fat accumulation in the body, which has recently become more prevalent and is the foremost risk factor for MAFLD. Causes of obesity may involve the interaction of genetic, behavioral, and social factors. m6A RNA methylation might add a novel inspiration for understanding the development of obesity and MAFLD with post-transcriptional regulation of gene expression. In particular, circRNAs, microRNAs (miRNAs), and m6A might be implicated in the progression of MAFLD. Interestingly, m6A modification can modulate the translation, degradation, and other functions of ncRNAs. miRNAs/circRNAs can also modulate m6A modifications by affecting writers, erasers, and readers. In turn, ncRNAs could modulate the expression of m6A regulators in different ways. However, there is limited evidence on how these ncRNAs and m6A interact to affect the promotion of liver diseases. It seems that m6A can occur in DNA, RNA, and proteins that may be associated with several biological properties. This study provides a mechanistic understanding of the association of m6A modification and ncRNAs with liver diseases, especially for MAFLD. Comprehension of the association between m6A modification and ncRNAs may contribute to the development of treatment tactics for MAFLD. Full article
(This article belongs to the Special Issue Non-coding RNAs: Multiple Players in Human Diseases)
Show Figures

Figure 1

28 pages, 2722 KiB  
Review
Role of Hydrogen Sulfide in Oncological and Non-Oncological Disorders and Its Regulation by Non-Coding RNAs: A Comprehensive Review
by Rana A. Youness, Danira Ashraf Habashy, Nour Khater, Kareem Elsayed, Alyaa Dawoud, Sousanna Hakim, Heba Nafea, Carole Bourquin, Reham M. Abdel-Kader and Mohamed Z. Gad
Non-Coding RNA 2024, 10(1), 7; https://doi.org/10.3390/ncrna10010007 - 18 Jan 2024
Cited by 6 | Viewed by 2716
Abstract
Recently, myriad studies have defined the versatile abilities of gasotransmitters and their synthesizing enzymes to play a “Maestro” role in orchestrating several oncological and non-oncological circuits and, thus, nominated them as possible therapeutic targets. Although a significant amount of work has been conducted [...] Read more.
Recently, myriad studies have defined the versatile abilities of gasotransmitters and their synthesizing enzymes to play a “Maestro” role in orchestrating several oncological and non-oncological circuits and, thus, nominated them as possible therapeutic targets. Although a significant amount of work has been conducted on the role of nitric oxide (NO) and carbon monoxide (CO) and their inter-relationship in the field of oncology, research about hydrogen sulfide (H2S) remains in its infancy. Recently, non-coding RNAs (ncRNAs) have been reported to play a dominating role in the regulation of the endogenous machinery system of H2S in several pathological contexts. A growing list of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are leading the way as upstream regulators for H2S biosynthesis in different mammalian cells during the development and progression of human diseases; therefore, their targeting can be of great therapeutic benefit. In the current review, the authors shed the light onto the biosynthetic pathways of H2S and their regulation by miRNAs and lncRNAs in various oncological and non-oncological disorders. Full article
(This article belongs to the Special Issue Non-coding RNAs: Multiple Players in Human Diseases)
Show Figures

Figure 1

14 pages, 643 KiB  
Review
Long Non-Coding RNAs (lncRNAs) in Heart Failure: A Comprehensive Review
by Shambhavi Jha, Vasanth Kanth Thasma Loganathbabu, Kasinathan Kumaran, Gopinath Krishnasamy and Kandasamy Nagarajan Aruljothi
Non-Coding RNA 2024, 10(1), 3; https://doi.org/10.3390/ncrna10010003 - 28 Dec 2023
Cited by 2 | Viewed by 3093
Abstract
Heart failure (HF) is a widespread cardiovascular condition that poses significant risks to a wide spectrum of age groups and leads to terminal illness. Although our understanding of the underlying mechanisms of HF has improved, the available treatments still remain inadequate. Recently, long [...] Read more.
Heart failure (HF) is a widespread cardiovascular condition that poses significant risks to a wide spectrum of age groups and leads to terminal illness. Although our understanding of the underlying mechanisms of HF has improved, the available treatments still remain inadequate. Recently, long non-coding RNAs (lncRNAs) have emerged as crucial players in cardiac function, showing possibilities as potential targets for HF therapy. These versatile molecules interact with chromatin, proteins, RNA, and DNA, influencing gene regulation. Notable lncRNAs like Fendrr, Trpm3, and Scarb2 have demonstrated therapeutic potential in HF cases. Additionally, utilizing lncRNAs to forecast survival rates in HF patients and distinguish various cardiac remodeling conditions holds great promise, offering significant benefits in managing cardiovascular disease and addressing its far-reaching societal and economic impacts. This underscores the pivotal role of lncRNAs in the context of HF research and treatment. Full article
(This article belongs to the Special Issue Non-coding RNAs: Multiple Players in Human Diseases)
Show Figures

Figure 1

Back to TopTop